Navigation Links
Oncolytics Biotech Inc. Announces 2007 Third Quarter Results
Date:10/30/2007

------------------------------------------------------

-------------------------------------------------------------------------

Stock based compensation for the third quarter of 2007 was $38,909 compared to $34,671 for the third quarter of 2006. In the third quarters of 2007 and 2006, we incurred stock based compensation associated with the vesting of previously granted options.

YEAR TO DATE RESULTS OF OPERATIONS

(for the nine months ended September 30, 2007 and 2006)

Net loss for the nine month period ending September 30, 2007 was $11,556,714 compared to $9,407,419 for the nine month period ending September 30, 2006.

Research and Development Expenses ("R&D")

2007 2006

$ $

-------------------------------------------------------------------------

Manufacturing and related process

development expenses 3,546,732 2,751,207

Clinical trial expenses 2,983,688 1,920,467

Pre-clinical trial and research

collaboration expenses 731,445 691,553

Other R&D expenses 1,553,390 1,219,460

-------------------------------------------------------------------------

Research and development expenses 8,815,255 6,582,687

-------------------------------------------------------------------------

-------------------------------------------------------------------------

For the nine month period ending September 30, 2007, R&D increased to $8,815,255 compared to $6,582,687 for 2006. The increase in R&D was due to the following:

Manufacturing & Related Process Development ("M&P")

2007 2006


'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29

Related biology technology :

1. The state of global biotech: An Ernst & Young perspective
2. Olympics of biotechnology has international flavor
3. Biotech officials praise focus of new venture fund
4. Getting noticed in Genetown: Wisconsin biotech on display
5. Madison biotech NimbleGen files for IPO; one of states best-funded firms
6. Wisconsin biotech firm receives $107K NIH grant
7. Biotech executive books a career flight thats closer to home
8. Manufacturing partnership will move into biotech and biomedical spaces
9. Wisconsin wont get Georgia biotech without a fight
10. The 10 biggest events shaping biotech in 2006
11. Gala Biotech among companies sold for $3.3 billion
Post Your Comments:
*Name:
*Comment:
*Email: